The process for discovery and development of biomarkers of solid tumors presents exceptional challenges. The major technical obstacle is the disconnection between the site of their generation (tissue, proximal fluid) and the source of detection (body fluids, predominantly serum and plasma). This single factor limits, in practical terms, the potential pool of biomarkers to those that are secreted, shed, or leaked from the cell surface. On reaching the circulation, a biomarker undergoes "dilution" into a mixture of thousands of proteins that are present at concentrations spanning at least 10 orders of magnitude. Furthermore, the integrity of a circulating biomarker may be compromised by proteolytic degradation or distortion of its posttranslational modifications. Other levels of complexity involve the inherent variability of biological systems (intraindividual and across a population) and ambiguities in defining disease phenotypes. Finally, fundamental and technological difficulties involved in biomarker studies are exacerbated by preanalytical variables associated with sample collection, handling, and storage (1, 2 ) .
An ideal cancer biomarker would be detectable in body fluids at an early stage of disease in a highly specific and selective fashion and be measurable for an inexpensive price. Development of such a biomarker is not a trivial endeavor. To promote efficiency and rigor in cancer biomarker research, Pepe et al. (3 ) introduced guidelines for a generally appropriate process that could be applied to many other diseases and classes of biomarker (e.g., a protein or a metabolite). These guidelines propose specific aims and measures of success for each of the 5 phases of a biomarker discovery pipeline in the context of progress being made in the field and relevant published studies. It is now evident that the majority of proteomics and genomics studies published to date do not progress far beyond the discovery stage (phase 1), because the development of clinical immunoassays (e.g., ELISA assays) required to move a multitude of putative biomarkers to the verification stage (phase 2) is prohibitively slow and expensive. Innovative approaches are necessary to accelerate biomarker credentialing and improve healthcare for cancer patients. To this end, the recent work of Whiteaker et al. (4 ) focuses on the process of proteomicsbased targeted verification of breast cancer biomarkers in plasma, currently a major bottleneck in the pipeline. The authors systematically address the challenges and provide a resounding "yes" to the question, "Can largescale verification of protein biomarkers in plasma be done with current proteomics technologies?" Their results clearly indicate that the protein biomarker discovery field is maturing.
Whiteaker et al. successfully deployed an efficient and standardized mass spectrometry-based pipeline of biomarker discovery and verification for credentialing putative biomarkers. This work used a well-characterized doxycycline-inducible, bitransgenic MMTV-rtTA/TetONeuNT (Her2/Neu) mouse model of breast cancer. The differential proteomics analyses also included samples from healthy transgenic TetO-Neu control mice. To avoid bias, the investigators paired experimental and control animals at weaning and matched them with respect to age, sex, litter, cage, and treatment protocols. Thus, biological and environmental variation was minimized, thereby decoupling sample-related interferences (e.g., interindividual differences) from noise inherent to the methods. The major focus of this work was verification, which built on the discovery data generated by the authors and other investigators with this animal model. In their study, the investigation reduced the initial pool of 1908 putative biomarkers that emerged from the discovery studies to a set of 36 proteins that were verified as increased in the plasma of tumor-bearing mice. Although the authors were aware that the complexity of their model is much lower than that of human cancer patients, they conducted a study that benchmarked the currently available technologies in a tightly controlled in vivo model. In doing so, they have provided a much needed reality check regarding the amount of effort required to generate high-quality data sets for identifying valuable biomarker targets worthy of further development.
The approach described by Whiteaker et al. encompassed 3 essential steps in the biomarker pipeline: discovery, triage, and verification. The discovery step used data from 13 independent microarray experiments and proteomics experiments, with the latter per-formed in an untargeted data-dependent (shotgun) fashion. The previous results were integrated, and candidates of interest were selected according to very specific preestablished criteria. For example, mRNAderived targets were included only if the protein product was observed in any of the multiple proteomics assays, and tissue-derived targets were confined to those predicted to be secreted, leaked, or shed. In all, 1908 candidates were selected for a stepwise triage process that used a series of targeted proteomics work flows of increasing stringency and sensitivity.
The goal of the first triage step was to identify the candidate biomarkers that were detectable in plasma, because many had originated from tissue-based studies. The best representative peptides for subsequent stages of analysis were also selected. To this end, accurate inclusion mass screening (AIMS) 3 (5 ) was used to detect biomarker candidates in pooled plasma samples from 20 tumor-bearing animals. AIMS uses a highresolution mass spectrometer (e.g., Orbitrap; Thermo Scientific) and enables preferential selection of peptide molecular ions for tandem mass spectrometry that have an accurate m/z at a specified charge state and within a predicted retention-time window. Targeting proteotypic peptides, i.e., those detectable under the experimental conditions and diagnostic for a given protein, is vital to the success of the AIMS approach. In the absence of empirical knowledge about proteotypic peptides and limits on work flow capacity, the authors eliminated from the AIMS analysis a subset of putative biomarkers that lacked prototypic peptides. The final tally was 1144 candidates represented by 16 961 peptides distributed among 21 inclusion lists. The AIMS analyses evaluated plasma samples depleted of the 7 most abundant proteins and identified 500 candidates. In addition, these experiments identified 72 proteins that were observed at a discovery stage but not included for AIMS; these proteins were added to the candidate pool. Not unexpectedly, the highest confirmation rates were for candidates that had previously been observed in plasma; however, 17% of the candidates that were originally discovered only in tissue were identified, including 2% that were derived exclusively from the mRNA analyses.
In the second triage step, Whiteaker et al. used a semiquantitative (SQ) application of selected reaction monitoring (SRM) to further cull their list of candidate biomarkers. In this targeted mass spectrometry approach, plasma proteins with the same abundance in tumor-bearing and control animals were used to normalize candidate proteins across liquid chromatography SRM mass spectrometry runs carried out with a triple-quadrupole mass spectrometer. Transitions (a pair of precursor and fragment ion m/z values for a given peptide) for 383 of the candidates were measured in depleted plasma pooled from 20 tumorbearing and 20 control mice. For the remainder, the observed peptides did not meet the SRM peptideselection criteria. Approximately 43% and 10% of the candidates were identified with high and medium confidence, respectively; the rest were classified as "unsubstantiated." The high-confidence candidates were further prioritized by ROC curve analyses that identified 49 proteins as increased in cancer. Next, quantitative assays were developed for 91 candidates prioritized by the SQ-SRM studies. A single multiplex assay [quantitative SRM (Q-SRM)] that used stable isotope-labeled peptides as internal standards was configured for 7 invariant proteins and 49 high-confidence candidates. In all, 57 peptides were targeted. In addition, stableisotope standards and capture by antipeptide antibodies (SISCAPA) (6 ) multiplex assays (immuno-SRM) were developed for 30 candidates from the SQ-SRM analyses that gave signals below the limit of quantification. Thus, these experiments enabled estimation of the false-negative rate. Performance was excellent for both assays, with a demonstrated linearity over 2-4 orders of magnitude and limits of detection and quantification in the interval of 10 -100 g/L for Q-SRM targets and 1-100 g/L for immuno-SRM targets. Imprecision was good, with median CVs well under 15%.
The final step of the pipeline was quantitative verification studies of plasma samples from individual animals, rather than pooled samples. The Q-SRM and immuno-SRM assays were deployed for the analysis of depleted and nondepleted plasma samples, respectively. Two cohorts of mice were studied: diseased mice with substantially advanced tumors (cohort 1) and mice in an early phase of the disease process (cohort 2). For cohort 1, 36 proteins (54% and 17% derived from Q-SRM and immuno-SRM assays, respectively) were significantly increased in plasma samples from experimental mice, compared with disease-free control mice. This result demonstrated the utility of the SQ-SRM approach for prioritizing candidates that can be detected and quantified with or without enrichment. Only 2 proteins circulated at significantly higher concentrations in the cohort 2 mice than in the controls, a result that exemplifies the considerable challenge of verifying biomarkers of early-stage tumors. As controls for disease specificity, plasma samples were obtained from cohort 3, which consisted of wild-type mice with confounding conditions-subcutaneous inflammation and necrosis, chronic inflammation resembling arthri-tis, and angiogenesis (30 diseased animals, 10 controls). Seventeen (42%) of the 36 proteins that were increased in cohort 1 animals were reliably quantified in at least 50% of the cohort 3 animals; only 2 proteins (approximately 12%) were significantly increased. Thus, the majority of the biomarkers verified in this study are likely to be specific for breast cancer.
In summary, the work by Whiteaker et al. (from the laboratory of Dr. Amanda Paulovich at the Fred Hutchinson Cancer Center) gives us an interesting glimpse into the future of mass spectrometry-based pipelines for biomarker discovery and verification. Importantly, of the 369 candidates selected solely on the basis of significant differences in mRNA production in tissue, only approximately 2% were confirmed by AIMS, and none were subsequently verified. Likewise, none of the 35 candidates revealed by the label-free proteomic-discovery assays of plasma alone were verified. These results clearly demonstrate that biomarker discovery investigations focused solely on plasma are very unlikely to be effective without including concomitant analyses of affected tissues (or proximal fluids) at the protein level. Given the inherent variability in the human population, it will be very interesting to learn whether the candidates identified by this study of genetically identical mice are biomarkers of human breast cancer and whether the analysis paradigm set forth in this important report can be successfully applied to human tumors and plasma/serum samples.
